Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma

1 Jan 2024

Abstract excerpt

BACKGROUND: Malignant glioma carries a poor prognosis despite current therapeutic modalities. Standard of care therapy consists of surgical resection, fractionated radiotherapy concurrently administered with temozolomide (TMZ), a DNA-alkylating chemotherapeutic agent, followed by adjuvant TMZ. O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair enzyme, removes alkylated lesions from tumor DNA, thereby...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38224404
DOI: 10.1007/s11060-023-04531-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant gliomaPMID 38224404Read ↗

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read ↗

Epigenetic modification and characterization of the <i>MGMT</i> promoter region using CRISPRoff in glioblastoma cellsSemantic proximity Read ↗

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapySemantic proximity Read ↗

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysisSemantic proximity Read ↗

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomasSemantic proximity Read ↗

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomasSemantic proximity Read ↗

Genetic and epigenetic landscape of O6-methylguanine-DNA methyltransferase (MGMT): implications for DNA repair and cancer therapeuticsSemantic proximity Read ↗

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.Semantic proximity Read ↗

In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastomaSemantic proximity Read ↗

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic ScreeningSemantic proximity Read ↗

The Role of the DNA Methyltransferase Family and the Therapeutic Potential of DNMT Inhibitors in Tumor TreatmentSemantic proximity Read ↗

Unlocking glioblastoma vulnerabilities with CRISPR-based genetic screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.